Chen C, Lavezzi S, McDougall D
Clin Transl Sci. 2024; 17(6):e13831.
PMID: 38808564
PMC: 11134224.
DOI: 10.1111/cts.13831.
Elsayed A, Pellegrino C, Pluss L, Peissert F, Benz R, Ulrich F
MAbs. 2023; 15(1):2220839.
PMID: 37288872
PMC: 10251795.
DOI: 10.1080/19420862.2023.2220839.
Menochet K, Yu H, Wang B, Tibbitts J, Hsu C, Kamath A
MAbs. 2022; 14(1):2145997.
PMID: 36418217
PMC: 9704389.
DOI: 10.1080/19420862.2022.2145997.
Joseph J, Gronbach L, Garcia-Miller J, Cruz L, Wuest B, Keilholz U
Pharmaceutics. 2020; 12(5).
PMID: 32366029
PMC: 7284432.
DOI: 10.3390/pharmaceutics12050413.
Kobold S, Pantelyushin S, Rataj F, Vom Berg J
Front Oncol. 2018; 8:285.
PMID: 30090763
PMC: 6068270.
DOI: 10.3389/fonc.2018.00285.
Revisiting CD28 Superagonist TGN1412 as Potential Therapeutic for Pediatric B Cell Leukemia: A Review.
Brown K
Diseases. 2018; 6(2).
PMID: 29783736
PMC: 6023298.
DOI: 10.3390/diseases6020041.
Biomarkers for nonclinical infusion reactions in marketed biotherapeutics and considerations for study design.
Mease K, Kimzey A, Lansita J
Curr Opin Toxicol. 2018; 4:1-15.
PMID: 29658009
PMC: 5893855.
DOI: 10.1016/j.cotox.2017.03.005.
Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.
van Gerven J, Bonelli M
Br J Clin Pharmacol. 2018; 84(7):1401-1409.
PMID: 29451320
PMC: 6005602.
DOI: 10.1111/bcp.13550.
Immuno-Oncology: The Third Paradigm in Early Drug Development.
Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J
Target Oncol. 2016; 12(2):125-138.
PMID: 27995439
DOI: 10.1007/s11523-016-0471-4.
Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.
Zhang Y, Doshi S, Zhu M
Br J Clin Pharmacol. 2015; 80(5):957-64.
PMID: 25912961
PMC: 4631169.
DOI: 10.1111/bcp.12663.
Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial.
Horvath C, Andrews L, Baumann A, Black L, Blanset D, Cavagnaro J
Nat Rev Immunol. 2012; 12(10):740.
PMID: 22941443
DOI: 10.1038/nri3192-c1.
Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.
Vugmeyster Y, Xu X, Theil F, Khawli L, Leach M
World J Biol Chem. 2012; 3(4):73-92.
PMID: 22558487
PMC: 3342576.
DOI: 10.4331/wjbc.v3.i4.73.
TGN1412: From Discovery to Disaster.
Attarwala H
J Young Pharm. 2010; 2(3):332-6.
PMID: 21042496
PMC: 2964774.
DOI: 10.4103/0975-1483.66810.
Preclinical development of monoclonal antibodies: considerations for the use of non-human primates.
Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J
MAbs. 2010; 1(5):505-16.
PMID: 20065651
PMC: 2759500.
DOI: 10.4161/mabs.1.5.9676.
Do we need a special ethics for research?.
Hansson S
Sci Eng Ethics. 2009; 17(1):21-9.
PMID: 19941087
DOI: 10.1007/s11948-009-9186-6.
